Immatics (NASDAQ:IMTXW) Short Interest Up 2,257.1% in December

Immatics (NASDAQ:IMTXW) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 16,500 shares, a growth of 2,257.1% from the November 30th total of 700 shares. Based on an average daily trading volume, of 33,600 shares, the short-interest ratio is currently 0.5 days.

Immatics Price Performance

Shares of Immatics stock traded down $0.01 on Thursday, hitting $0.18. The company’s stock had a trading volume of 1,832 shares, compared to its average volume of 15,750. The firm has a fifty day moving average price of $0.64 and a 200-day moving average price of $1.99. Immatics has a 1 year low of $0.18 and a 1 year high of $4.14.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.